Genentech’s Sean Bohen defects to AstraZeneca as CMO

01/09/2015 - 2 minutes

AstraZeneca‘s Senior management team gets reinforced by Sean Bohen, a top executive from Roche‘s subsidiary Genentech. Starting in two weeks, he will push late-stage treatments to the market. 

It’s been two months since two senior manager left the struggling AstraZeneca. Among them, Briggs Morrison, who left to become new CEO of Syndax. To replace him, Astra gets a former colleague from its CEO Pascal Soriot on board: Sean Bohen. Like Soriot, he comes to the company after working for Roche.

Bohen will help the potential treatments through late-stage development to the market. A bit of a change from his former tasks at Genentech, where he oversaw early stage development of the potential treatments to get them into the stage where he will be active now.

Prior to joining Genentech, he worked as clinical instructor for Oncology at Stanford University School of Medicine. Both work experiences gave Bohen expertise in therapy areas that both companies share, particularly in cancer,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member